Bayer’s kidney disease drug Kerendia reduces cardiovascular risk by 16%

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.
Bayer, seeking to expand the approval of Kerendia (finerenone) after an initial approval in kidney disease three years ago, is back with data showing that the mineralocorticoid receptor antagonist reduced the risk of cardiovascular death and heart failure by 16%.